Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB (MPSIIIB)
Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
The Nationwide Children’s Hospital in Columbus, OH, is recruiting patients with Mucopolysaccharidosis (MPS) IIIB (MPSIIIB) for a clinical trial of a gene therapy that will attempt to impart a functional copy of the NAGLU gene. This therapy is a genetically-engineered virus that delivers the gene, and treatment will involve a one-time infusion in addition to a tapering course of steroids. Improved health and cognitive ability are some of the goals of this treatment.
Follow up for 2 years will include lab testing and clinical assessments to track NAGLU enzyme activities and overall health.
- Be 6 months of age or older
- Have a confirmed diagnosis of MPSIIIB by both of the following two methods:
- No detectable or significantly reduced NAGLU enzyme activity by plasma, serum, or leukocyte assay.
- Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the NAGLU gene
- Not have received prior treatment with NAGLU enzyme replacement therapy (ERT)
THE STUDY INVOLVES:
- Screening before the treatment, possibly including DNA assessments
- A single infusion of the gene therapy drug will be administered at one of two dose levels.
- Monitoring of the patient for a few hours after dosing, with lab, physical, and cognitive assessments required for up to 2 years post treatment.
LOCATIONS AND CONTACTS:
Trials will take place at the Nationwide Children’s Hospital in Columbus, OH. Map.
Federica Rinaldi, PhD | 614-355-2897 | [email protected]
Tabatha Simmons, PhD | 614-722-6921 | [email protected]
Abeona Therapeutics, Inc
Or go online: